NCT04955535

Brief Summary

This study retrospectively analyzed the history of present illness of PVNS patients in our hospital. The enrolled patients were followed up by telephone to follow up their postoperative recovery and living conditions. Take the patient's pathological specimens for immunohistochemical testing, evaluate the relationship between the expression of different molecular targets, clinical manifestations and patient prognosis, and explore new molecular targets related to disease diagnosis and treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 3, 2020

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 27, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 27, 2020

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

June 25, 2021

Completed
13 days until next milestone

First Posted

Study publicly available on registry

July 8, 2021

Completed
Last Updated

July 8, 2021

Status Verified

June 1, 2021

Enrollment Period

5 months

First QC Date

June 25, 2021

Last Update Submit

July 7, 2021

Conditions

Pigmented Villonodular Synovitis

Outcome Measures

Primary Outcomes (6)

  • Difference of scale score between immunohistochemistry positive group and negative group

    Difference of Visual Analog Score for pain between CSF-1 immunohistochemistry positive group and negative group

    One week after surgery

  • Difference of Visual Analog Score for pain between TNF-α immunohistochemistry positive group and negative group

    Difference of Visual Analog Score for pain between TNF-α immunohistochemistry positive group and negative group

    One week after surgery

  • Difference of Visual Analog Score for pain between IL-1B immunohistochemistry positive group and negative group

    Difference of Visual Analog Score for pain between IL-1B immunohistochemistry positive group and negative group

    One week after surgery

  • Difference of SF-36 score between CSF-1 immunohistochemistry positive group and negative group

    Difference of SF-36 score between CSF-1 immunohistochemistry positive group and negative group

    One week after surgery

  • Difference of SF-36 score between TNF-α immunohistochemistry positive group and negative group

    Difference of SF-36 score between TNF-α immunohistochemistry positive group and negative group

    One week after surgery

  • Difference of SF-36 score between IL-1B immunohistochemistry positive group and negative group

    Difference of SF-36 score between IL-1B immunohistochemistry positive group and negative group

    One week after surgery

Secondary Outcomes (1)

  • Correlation between basic demographic characteristics and scale scores

    One week after surgery

Interventions

Arthroscopic synovectomyPROCEDURE

Arthroscopic synovectomy

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients with "pigmented villonodular synovitis" and "giant cell tumor of tendon sheath"

You may qualify if:

  • Clinical diagnosis of pigmented villonodular synovitis.
  • Clinical diagnosis of giant cell tumor of tendon sheath

You may not qualify if:

  • No surgical treatment.
  • There were no pathological specimens during the operation.
  • The age of the patient is less than 18 years old or more than 60 years old.
  • The operation record shows nodular type.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute of Sports Medicine, Peking University Third Hospital, Beijing Key Laboratory of Sports Injuries， Beijing, China

Beijing, Beijing Municipality, 100191, China

Location

MeSH Terms

Conditions

Synovitis, Pigmented Villonodular

Condition Hierarchy (Ancestors)

Giant Cell Tumor of Tendon SheathGiant Cell TumorsNeoplasms, Connective TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsSynovitisJoint DiseasesMusculoskeletal DiseasesTendinopathyMuscular Diseases

Study Officials

  • Yingfang Ao, Prof.

    Peking Yniversity Third Hospital

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 25, 2021

First Posted

July 8, 2021

Study Start

August 3, 2020

Primary Completion

December 27, 2020

Study Completion

December 27, 2020

Last Updated

July 8, 2021

Record last verified: 2021-06

Locations

CN(1)